NCT05637255CompletedPhase 2
A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)
A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular AMD
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
The goal of this clinical trial is to compare the safety and effect on visual acuity of three different doses of SYL1801 eye drops.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 99 (actual)
- First submitted
- 16 Nov 2022
- Start date
- 22 Nov 2022
- Primary completion date
- 19 Dec 2024
- Lead sponsor
- Sylentis, S.A.
- Diseases
- Macular degeneration
- NCT number
- NCT05637255
- EudraCT number
- 2022-000214-34
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 99
- From 22 Nov 2022 to the primary completion date, 19 Dec 2024
- 15 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current, previous chronic or recurrent condition according to the investigator's judgement.
- Concomitant treatment or prior ocular procedure or surgery, or alteration of the dose of systemic medications
- Concurrent disease in the study eye
- Previous treatment with systemic anti-Vascular Endothelial Growing Factor (Anti-VEGF) drugs or pro-VEGF treatments
- Concurrent disease in the study eye, other than AMD
Other
- Pregnant or breastfeeding females or those with a positive pregnancy test.
- Females of childbearing potential who will not use a medically acceptable contraceptive method
Who the study is looking for
- Signed informed consent
- Active subfoveal or juxtafoveal choroidal neovascularization secondary to AMD
- Best Corrected Visual Acuity (BCVA) between 70-25 letters (ETDRS) at Screening
- Intraretinal or subretinal fluid
- Central Subfield Thickness \> 300 µm
Age in the registry: 50 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (15)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.